Now showing items 1-20 of 35

    • Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. 

      Woods, BS; Sideris, E; Sydes, MR; Gannon, MR; Parmar, MKB; Alzouebi, M; Attard, G; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, PR; Cook, A; Cross, WR; Dearnaley, DP; Gale, J; Gibbs, S; Graham, JD; Hughes, R; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Peedell, C; Protheroe, A; Ritchie, AWS; Robinson, A; Russell, JM; Simms, MS; Srihari, NN; Srinivasan, R; Staffurth, JN; Sundar, S; Thalmann, GN; Tolan, S; Tran, ATH; Tsang, D; Wagstaff, J; James, ND; Sculpher, MJ (2018-12)
      BACKGROUND:Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic ...
    • Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. 

      Bonilla, C; Lewis, SJ; Rowlands, M-A; Gaunt, TR; Davey Smith, G; Gunnell, D; Palmer, T; Donovan, JL; Hamdy, FC; Neal, DE; Eeles, R; Easton, D; Kote-Jarai, Z; Al Olama, AA; Benlloch, S; Muir, K; Giles, GG; Wiklund, F; Grönberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Pashayan, N; Khaw, K-T; Stanford, JL; Blot, WJ; Thibodeau, S; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Pandha, H; PRACTICAL consortium; Lathrop, M; Martin, RM; Holly, JMP (2016-10)
      Circulating insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) are associated with prostate cancer. Using genetic variants as instruments for IGF peptides, we investigated whether these associations are ...
    • Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. 

      Saya, S; Killick, E; Thomas, S; Taylor, N; Bancroft, EK; Rothwell, J; Benafif, S; Dias, A; Mikropoulos, C; Pope, J; Chamberlain, A; Gunapala, R; SIGNIFY Study Steering Committee; Izatt, L; Side, L; Walker, L; Tomkins, S; Cook, J; Barwell, J; Wiles, V; Limb, L; Eccles, D; Leach, MO; Shanley, S; Gilbert, FJ; Hanson, H; Gallagher, D; Rajashanker, B; Whitehouse, RW; Koh, D-M; Sohaib, SA; Evans, DG; Eeles, RA (2017-07)
      In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to ...
    • BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). 

      Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; Protheroe, A; Bogle, R; Blazeby, J; Palmer, A; Cresswell, J; Johnson, M; Brough, R; Madaan, S; Andrews, S; Cruickshank, C; Burnett, S; Maynard, L; Hall, E; BOXIT Investigators (2019-04)
      BACKGROUND:Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE:To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk ...
    • BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). 

      Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; Protheroe, A; Bogle, R; Blazeby, J; Palmer, A; Cresswell, J; Johnson, M; Brough, R; Madaan, S; Andrews, S; Cruickshank, C; Burnett, S; Maynard, L; Hall, E; BOXIT Investigators (2019-04)
      BACKGROUND:Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE:To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk ...
    • Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent. 

      Johnson, L; O'Donoghue, JM; McLean, N; Turton, P; Khan, AA; Turner, SD; Lennard, A; Collis, N; Butterworth, M; Gui, G; Bristol, J; Hurren, J; Smith, S; Grover, K; Spyrou, G; Krupa, K; Azmy, IA; Young, IE; Staiano, JJ; Khalil, H; MacNeill, FA (2017-08)
      Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare, Non-Hodgkin lymphoma arising in the capsule of breast implants. BIA-ALCL presents as a recurrent effusion and/or mass. Tumours exhibit CD30 ...
    • Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. 

      Adams, CD; Richmond, R; Ferreira, DLS; Spiller, W; Tan, V; Zheng, J; Würtz, P; Donovan, J; Hamdy, F; Neal, D; Lane, JA; Smith, GD; Relton, C; Eeles, RA; Haiman, CA; Kote-Jarai, Z; Schumacher, FR; Olama, AAA; Benlloch, S; Muir, K; Berndt, SI; Conti, DV; Wiklund, F; Chanock, SJ; Gapstur, S; Stevens, VL; Tangen, CM; Batra, J; Clements, JA; Gronberg, H; Pashayan, N; Schleutker, J; Albanes, D; Wolk, A; West, CML; Mucci, LA; Cancel-Tassin, G; Koutros, S; Sorensen, KD; Maehle, L; Travis, RC; Hamilton, RJ; Ingles, SA; Rosenstein, BS; Lu, Y-J; Giles, GG; Kibel, AS; Vega, A; Kogevinas, M; Penney, KL; Park, JY; Stanford, JL; Cybulski, C; Nordestgaard, BG; Brenner, H; Maier, C; Kim, J; John, EM; Teixeira, MR; Neuhausen, SL; De Ruyck, K; Razack, A; Newcomb, LF; Lessel, D; Kaneva, RP; Usmani, N; Claessens, F; Townsend, PA; Dominguez, MG; Roobol, MJ; Menegaux, F; Khaw, K-T; Cannon-Albright, LA; Pandha, H; Thibodeau, SN; Martin, RM; PRACTICAL consortium (2019-01)
      BACKGROUND:Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and appraise ...
    • COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. 

      Crabb, SJ; Martin, K; Abab, J; Ratcliffe, I; Thornton, R; Lineton, B; Ellis, M; Moody, R; Stanton, L; Galanopoulou, A; Maishman, T; Geldart, T; Bayne, M; Davies, J; Lamb, C; Popat, S; Joffe, JK; Nutting, C; Chester, J; Hartley, A; Thomas, G; Ottensmeier, C; Huddart, R; King, E (2017-12)
      BACKGROUND:Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common ...
    • Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). 

      Andronis, L; Goranitis, I; Pirrie, S; Pope, A; Barton, D; Collins, S; Daunton, A; McLaren, D; O'Sullivan, JM; Parker, C; Porfiri, E; Staffurth, J; Stanley, A; Wylie, J; Beesley, S; Birtle, A; Brown, JE; Chakraborti, P; Hussain, SA; Russell, JM; Billingham, LJ; James, ND (2017-04)
      To evaluate the cost-effectiveness of adding zoledronic acid or strontium-89 to standard docetaxel chemotherapy for patients with castrate-refractory prostate cancer (CRPC).Data on resource use and quality of life for 707 ...
    • Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams). 

      Grønhøj, C; Jensen, DH; Dehlendorff, C; Marklund, L; Wagner, S; Mehanna, H; Munck-Wikland, E; Ramqvist, T; Näsman, A; Wittekindt, C; Würdemann, N; Sharma, SJ; Gattenlöhner, S; Kiss, K; Andersen, E; Spruce, R; Batis, N; Robinson, M; Harrington, K; Winter, S; Jones, TM; Klussmann, JP; Dalianis, T; Friborg, J; von Buchwald, C (2018-06)
      BACKGROUND:The proxy marker for human papillomavirus (HPV), p16, is included in the new AJCC 8th/UICC 8th staging system, but due to incongruence between p16 status and HPV infection, single biomarker evaluation could lead ...
    • Dietary fat and early-onset prostate cancer risk. 

      Lophatananon, A; Archer, J; Easton, D; Pocock, R; Dearnaley, D; Guy, M; Kote-Jarai, Z; O'Brien, L; Wilkinson, RA; Hall, AL; Sawyer, E; Page, E; Liu, J-F; Barratt, S; Rahman, AA; UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology; Eeles, R; Muir, K (2010-05)
      The UK incidence of prostate cancer has been increasing in men aged < 60 years. Migrant studies and global and secular variation in incidence suggest that modifiable factors, including a high-fat diet, may contribute to ...
    • An external dosimetry audit programme to credential static and rotational IMRT delivery for clinical trials quality assurance. 

      Eaton, DJ; Tyler, J; Backshall, A; Bernstein, D; Carver, A; Gasnier, A; Henderson, J; Lee, J; Patel, R; Tsang, Y; Yang, H; Zotova, R; Wells, E (2017-03)
      External dosimetry audits give confidence in the safe and accurate delivery of radiotherapy. The RTTQA group have performed an on-site audit programme for trial recruiting centres, who have recently implemented static or ...
    • Genetic predisposition to prostate cancer. 

      Benafif, S; Eeles, R (2016-12)
      INTRODUCTION:Prostate cancer (PrCa) is the commonest non-cutaneous cancer in men in the UK. Epidemiological evidence as well as twin studies points towards a genetic component contributing to aetiology. SOURCES OF DATA:Key ...
    • Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. 

      Copson, ER; Maishman, TC; Tapper, WJ; Cutress, RI; Greville-Heygate, S; Altman, DG; Eccles, B; Gerty, S; Durcan, LT; Jones, L; Evans, DG; Thompson, AM; Pharoah, P; Easton, DF; Dunning, AM; Hanby, A; Lakhani, S; Eeles, R; Gilbert, FJ; Hamed, H; Hodgson, S; Simmonds, P; Stanton, L; Eccles, DM (2018-02)
      BACKGROUND:Retrospective studies provide conflicting interpretations of the effect of inherited genetic factors on the prognosis of patients with breast cancer. The primary aim of this study was to determine the effect of ...
    • HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. 

      Schache, AG; Powell, NG; Cuschieri, KS; Robinson, M; Leary, S; Mehanna, H; Rapozo, D; Long, A; Cubie, H; Junor, E; Monaghan, H; Harrington, KJ; Nutting, CM; Schick, U; Lau, AS; Upile, N; Sheard, J; Brougham, K; West, CML; Oguejiofor, K; Thomas, S; Ness, AR; Pring, M; Thomas, GJ; King, EV; McCance, DJ; James, JA; Moran, M; Sloan, P; Shaw, RJ; Evans, M; Jones, TM (2016-11)
      A rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) incidence has occurred throughout the developed world, where it has been attributed to an increasing impact of human papillomavirus (HPV) on disease ...
    • Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. 

      Murray Brunt, A; Haviland, JS; Wheatley, DA; Sydenham, MA; Alhasso, A; Bloomfield, DJ; Chan, C; Churn, M; Cleator, S; Coles, CE; Goodman, A; Harnett, A; Hopwood, P; Kirby, AM; Kirwan, CC; Morris, C; Nabi, Z; Sawyer, E; Somaiah, N; Stones, L; Syndikus, I; Bliss, JM; Yarnold, JR; FAST-Forward Trial Management Group (2020-05)
      BACKGROUND:We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard ...
    • Laryngeal cancer: United Kingdom National Multidisciplinary guidelines. 

      Jones, TM; De, M; Foran, B; Harrington, K; Mortimore, S (2016-05)
      This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Significantly new data have been published on laryngeal cancer management since the ...
    • MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. 

      Walker, AK; Karaszi, K; Valentine, H; Strauss, VY; Choudhury, A; McGill, S; Wen, K; Brown, MD; Ramani, V; Bhattarai, S; Teo, MTW; Yang, L; Myers, KA; Deshmukh, N; Denley, H; Browning, L; Love, SB; Iyer, G; Clarke, NW; Hall, E; Huddart, R; James, ND; Hoskin, PJ; West, CML; Kiltie, AE (2019-07)
      PURPOSE:Organ-confined muscle-invasive bladder cancer is treated with cystectomy or bladder preservation techniques, including radiation therapy. There are currently no biomarkers to inform management decisions and aid ...
    • A multicentre study of the evidence for customized margins in photon breast boost radiotherapy. 

      Harris, EJ; Mukesh, MB; Donovan, EM; Kirby, AM; Haviland, JS; Jena, R; Yarnold, J; Baker, A; Dean, J; Eagle, S; Mayles, H; Griffin, C; Perry, R; Poynter, A; Coles, CE; Evans, PM; IMPORT high trialists (2016-01)
      OBJECTIVE:To determine if subsets of patients may benefit from smaller or larger margins when using laser setup and bony anatomy verification of breast tumour bed (TB) boost radiotherapy (RT). METHODS:Verification imaging ...
    • Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. 

      Coles, CE; Griffin, CL; Kirby, AM; Titley, J; Agrawal, RK; Alhasso, A; Bhattacharya, IS; Brunt, AM; Ciurlionis, L; Chan, C; Donovan, EM; Emson, MA; Harnett, AN; Haviland, JS; Hopwood, P; Jefford, ML; Kaggwa, R; Sawyer, EJ; Syndikus, I; Tsang, YM; Wheatley, DA; Wilcox, M; Yarnold, JR; Bliss, JM; IMPORT Trialists (2017-09)
      BACKGROUND:Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that ...